Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + capecitabine for advanced biliary cancer
ACTRN12615000504516Phase 2Completed
- Sponsor
- Illawarra Shoalhaven Local Health District
- Start
- Aug 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and capecitabine in biliary cancer, sponsored by Illawarra Shoalhaven Local Health District. Primary endpoints: Feasibility of delivering second-line treatment in advanced biliary cancer and Safety and tolerability. Started Aug 2015; status: completed.
02
Drugs
paclitaxelcapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ACTRN12615000504516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000504516.